Tag:
Androxal
Latest Headlines
Latest Headlines
Repros shares boom on promising PhIII results for testosterone drug
Shares of Repros Therapeutics rocketed up 78% this morning after the Texas-based biotech announced that its roller coaster ride in a Phase III study for its experimental testosterone-boosting therapy Androxal ended on a positive note on a pair of co-primary endpoints.
Repros shares slide after FDA advises new Androxal study
Regulators at the FDA have told Repros Therapeutics ( $RPRXD ) that its testosterone drug Androxal is not ready for Phase III. Instead, the developer says the agency has asked for a fresh Phase IIb
Repros shares skyrocket on promising testosterone data
Repros Therapeutics got a badly needed lift this morning after it announced that a small study of Androxal demonstrated its ability to restore sperm count and boost testosterone levels in men with
